A single droplet digital PCR for ESR1 activating mutations detection in plasma

ESR1 mutations: a new biomarker in breast cancer

(2019) Marcela Carausu et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

(2018) Ben O’Leary et al.   Nature Communications

High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy

(2018) Laura Lupini et al.   Scientific Reports

Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions

(2018) Charles Decraene et al.   Jove-Journal of Visualized Experiments

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients

(2017) Takashi Takeshita et al.   Oncotarget

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay

(2016) Roza Bidshahri et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors

(2016) Y. Seki et al.   ONCOLOGIST

ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists

(2016) Weiyi Toy et al.   Cancer Discovery

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

(2016) Florian Clatot et al.   Oncotarget

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole

(2016) Rekha Gyanchandani et al.   Oncotarget

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer

(2016) Sarat Chandarlapaty et al.   JAMA Oncology

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

(2015) D. Chu et al.   CLINICAL CANCER RESEARCH

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

(2015) P. Wang et al.   CLINICAL CANCER RESEARCH

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

(2015) Gaia Schiavon et al.   Science Translational Medicine

Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens

(2015) Takashi Takeshita et al.   Translational Research

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients

(2015) Jiaxin Niu et al.   OncoTargets and Therapy

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

(2013) K. Merenbakh-Lamin et al.   CANCER RESEARCH

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Going with the Flow: From Circulating Tumor Cells to DNA

(2013) F.-C. Bidard et al.   Science Translational Medicine

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports